Kura Oncology, Inc.

Kura Oncology, Inc. has modified the severance provisions in the employment agreements for its Chairman, President, and CEO, Dr. Troy E. Wilson, and for its Chief Commercial Officer, Brian Powl, and Chief Operating Officer, Kathleen Ford. The updated agreements detail severance packages for termination without cause or resignation for good reason, with enhanced benefits in the event of a corporate transaction. These modifications clarify the terms of executive compensation and protection.

Kura Oncology announced positive updated Phase 1a results from the FIT-001 clinical trial for darlifarnib plus cabozantinib in advanced clear cell renal cell carcinoma (ccRCC). The combination demonstrated encouraging and durable clinical activity, with response rates up to 50% and a median progression-free survival of 13 months in pre-treated, cabozantinib-naïve patients. The therapy was well tolerated, and its safety profile was consistent with individual agents, supporting continued development towards a planned registrational study in 2028.

Kura Oncology announced updated Phase 1a results from its FIT-001 clinical trial, evaluating darlifarnib in combination with cabozantinib for advanced renal cell carcinoma (RCC), will be presented at the 2026 Kidney Cancer Research Summit. The data is expected to further support darlifarnib's potential to enhance VEGFR-targeted therapies. The company is also enrolling patients in a randomized Phase 1b study and plans a registrational Phase 3 study for 2028. Kura Oncology will host an investor call on July 27, 2026, to discuss these updates.

Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards to five new employees on July 1, 2026. These awards consist of nonstatutory stock options to purchase a total of 68,750 shares of common stock. The exercise price for these options is $10.78 per share, matching the closing price on the grant date, and they will vest over four years.

Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced encouraging long-term results from the Phase 1/2 KOMET-007 trial evaluating ziftomenib in combination with intensive chemotherapy (7+3) for newly diagnosed NPM1-m or KMT2A-r AML. The trial demonstrated a 94% 12-month overall survival rate in NPM1-m AML patients and 71% in KMT2A-r AML patients, along with high composite complete remission rates of 96% and 90% respectively. These favorable results, including deep molecular responses and a manageable safety profile, strengthen confidence in the ongoing Phase 3 KOMET-017 registrational study. Kura Oncology will host a virtual investor event to discuss these findings.

Kura Oncology, Inc. announced that its Compensation Committee granted inducement awards consisting of 53,000 nonstatutory stock options to four new employees on June 1, 2026. The options have an exercise price of $9.04 per share, which was the closing price of the company's common stock on the grant date. These awards will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting monthly over 36 months, subject to continued employment.

Kura Oncology, Inc. held its Annual Meeting of Stockholders where shareholders approved amendments to the 2014 Equity Incentive Plan and the 2015 Employee Stock Purchase Plan, increasing the number of authorized shares for each. The company also saw the election of three Class III directors and the ratification of Ernst & Young LLP as its independent auditor. Additionally, advisory votes on executive compensation and the frequency of such votes were passed.

Kura Oncology presented new clinical and translational data at ASCO 2026, supporting darlifarnib as a potential foundational combination platform for KRAS-mutant cancers. Preliminary Phase 1a data from darlifarnib plus adagrasib demonstrated confirmed objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer. The company plans a new platform study to accelerate evaluation of darlifarnib across multiple targeted therapies, with the first combination (darlifarnib + daraxonrasib) expected to enter Phase 1a in early 2027.

Kura Oncology and Kyowa Kirin announced the publication of updated positive Phase 1a/b KOMET-007 trial results for ziftomenib in combination with venetoclax and azacitidine for relapsed/refractory NPM1-mutated AML. The data showed robust clinical activity, including high objective response rates and composite complete remission rates, particularly in venetoclax-naïve patients, with deep molecular responses and durable remissions. The investigational three-drug combination was well tolerated, supporting its continued evaluation in ongoing studies, including pivotal Phase 3 trials.

Kura Oncology reported compelling first-in-human data from its FIT-001 clinical trial of darlifarnib in combination with adagrasib for KRAS G12C-mutated advanced solid tumors. The trial demonstrated 77% tumor shrinkage in response-evaluable patients, including those heavily pretreated and KRASi-experienced. Objective response rates were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-naïve CRC patients, reinforcing darlifarnib's potential as a precision combination agent with a manageable safety profile. These results will be presented at the 2026 ASCO Annual Meeting, and the company will host a virtual investor event on June 3, 2026.